Predictive value of p53 expression in the risk of malignant gastrointestinal stromal tumors: Evidence from 19 studies

Abstract

Abstract. The current published data on p53 expression and its predictive value in the risk of malignant gastrointestinal stromal tumors (GIST) has are inconclusive. To derive a more precise estimation of the correlation between p53 and the biological behavior of GIST, a meta-analysis was performed. Studies were identified by searching PubMed and Embase. Inclusion criteria were GIST patients, and the evaluation of p53 expression and risk of malignancy. The odds ratio (OR) for a positive rate of p53 in the benign group vs. that in the malignant group and the ORs for the positive rate of p53 in the National Institutes of Health (NIH) very low risk + low risk group (VL+L) vs. the NIH intermediate risk + high risk (I+H) group were calculated with a 95% confidence interval (CI) for each study as an estimation of the predictive value of p53. A total of 19 studies including 1163 patients were involved in this meta-analysis. The overall OR for the positive rate of p53 in the malignant group vs. the benign group revealed that significantly elevated risks of positive p53 in the malignant group were achieved (OR 0.14, 95% CI: 0.06-0.31, P<0.00001, P heterogeneity =0.86). Moreover, significantly elevated risks of correlation between p53 expression and the NIH I+H group were achieved in the comparison of the NIH VL+L group vs. the NIH I+H group (OR, 0.25; 95% CI, 0.17-0.38; P<0.00001, P heterogeneity =0.04). The results indicate that p53 expression correlates with poor prognosis in GIST and has a close relationship within the NIH I+H group.

Mixed adenocarcinoma, sarcomatoid carcinoma and adenosquamous carcinoma of the prostate: A case report

“…Additionally, the p53 protein level in the biopsy samples was evaluated by IHC. To the best of our knowledge, IHC staining should be positive for wild-type p53 and for mutant-type p53, but the wild-type p53 is only barely detectable by IHC ( 6 ). The half-life of the wild-type p53 protein is short, but mutant p53 exhibits an altered structure that confers a longer half-life and greater stability compared with wild-type p53.…”

“…The half-life of the wild-type p53 protein is short, but mutant p53 exhibits an altered structure that confers a longer half-life and greater stability compared with wild-type p53. As a result, the majority of positive cells represent mutant p53 ( 6 ). p53 is an important tumor suppressor that is involved in numerous molecular events, such as the regulation of DNA repair, apoptosis and senescence, and it is induced by various stress signals, including DNA damage and inflammation ( 7 ).…”

Prognostic significance of promyelocytic leukemia expression in gastrointestinal stromal tumor; integrated proteomic and transcriptomic analysis

“…GIST with high‐risk of recurrence show significant changes in genes that regulate the cell cycle . TP53 mutations, p53 overexpression and MDM2 amplification are correlated with poor outcome in GIST patients . The PI3K‐mTOR signaling pathway is one of the most important for growth of GIST cells .…”